Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 10/2013

01.10.2013 | Original Article

Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patients

verfasst von: Eline E. Verwer, Floris H. P. van Velden, Idris Bahce, Maqsood Yaqub, Robert C. Schuit, Albert D. Windhorst, Pieter Raijmakers, Adriaan A. Lammertsma, Egbert F. Smit, Ronald Boellaard

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

[18F]Fluoroazomycin arabinoside (FAZA) is a positron emission tomography (PET) tracer developed to enable identification of hypoxic regions within a tumour. The aims of this study were to determine the optimal kinetic model along with validation of using alternatives to arterial blood sampling for analysing [18F]FAZA studies and to assess the validity of simplified analytical methods.

Methods

Dynamic 70-min [18F]FAZA PET/CT scans were obtained from nine non-small cell lung cancer patients. Continuous arterial blood sampling, together with manual arterial and venous sampling, was performed to derive metabolite-corrected plasma input functions. Volumes of interest (VOIs) were defined for tumour, healthy lung muscle and adipose tissue generating [18F]FAZA time-activity curves (TACs). TACs were analysed using one- and two-tissue compartment models using both metabolite-corrected blood sampler plasma input functions (BSIF) and image-derived plasma input functions (IDIF).

Results

The reversible two-tissue compartment model with blood volume parameter (2T4k+VB) best described kinetics of [18F]FAZA in tumours. Volumes of distribution (VT) obtained using IDIF correlated well with those derived using BSIF (R 2 = 0.82). Venous samples yielded the same radioactivity concentrations as arterial samples for times >50 min post-injection (p.i.). In addition, both plasma to whole blood ratios and parent fractions were essentially the same for venous and arterial samples. Both standardised uptake value (SUV), normalised to lean body mass, and tumour to blood ratio correlated well with VT (R 2 = 0.77 and R 2 = 0.87, respectively, at 50–60 min p.i.), although a bias was observed at low VT.

Conclusion

The 2T4k+VB model provided the best fit to the dynamic [18F]FAZA data. IDIF with venous blood samples can be used as input function. Further data are needed to validate the use of simplified methods.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007;26(2):225–39.PubMedCrossRef Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007;26(2):225–39.PubMedCrossRef
2.
Zurück zum Zitat Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005;46(2):253–60.PubMed Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005;46(2):253–60.PubMed
3.
Zurück zum Zitat Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 2006;24(13):2098–104.PubMedCrossRef Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 2006;24(13):2098–104.PubMedCrossRef
4.
Zurück zum Zitat Beck R, Röper B, Carlsen JM, Huisman MC, Lebschi JA, Andratschke N, et al. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. J Nucl Med 2007;48(6):973–80.PubMedCrossRef Beck R, Röper B, Carlsen JM, Huisman MC, Lebschi JA, Andratschke N, et al. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. J Nucl Med 2007;48(6):973–80.PubMedCrossRef
5.
Zurück zum Zitat Grosu AL, Souvatzoglou M, Röper B, Dobritz M, Wiedenmann N, Jacob V, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007;69(2):541–51.PubMedCrossRef Grosu AL, Souvatzoglou M, Röper B, Dobritz M, Wiedenmann N, Jacob V, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007;69(2):541–51.PubMedCrossRef
6.
Zurück zum Zitat Busk M, Horsman MR, Jakobsen S, Hansen KV, Bussink J, van der Kogel A, et al. Can hypoxia-PET map hypoxic cell density heterogeneity accurately in an animal tumor model at a clinically obtainable image contrast? Radiother Oncol 2009;92(3):429–36.PubMedCrossRef Busk M, Horsman MR, Jakobsen S, Hansen KV, Bussink J, van der Kogel A, et al. Can hypoxia-PET map hypoxic cell density heterogeneity accurately in an animal tumor model at a clinically obtainable image contrast? Radiother Oncol 2009;92(3):429–36.PubMedCrossRef
7.
Zurück zum Zitat Arabi M, Piert M. Hypoxia PET/CT imaging: implications for radiation oncology. Q J Nucl Med Mol Imaging 2010;54(5):500–9.PubMed Arabi M, Piert M. Hypoxia PET/CT imaging: implications for radiation oncology. Q J Nucl Med Mol Imaging 2010;54(5):500–9.PubMed
8.
Zurück zum Zitat Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med 2008;49 Suppl 2:129S–48.PubMedCrossRef Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med 2008;49 Suppl 2:129S–48.PubMedCrossRef
9.
Zurück zum Zitat Lee ST, Scott AM. Hypoxia positron emission tomography imaging with 18F-fluoromisonidazole. Semin Nucl Med 2007;37(6):451–61.PubMedCrossRef Lee ST, Scott AM. Hypoxia positron emission tomography imaging with 18F-fluoromisonidazole. Semin Nucl Med 2007;37(6):451–61.PubMedCrossRef
10.
Zurück zum Zitat Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995;22(3):265–80.PubMedCrossRef Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995;22(3):265–80.PubMedCrossRef
11.
Zurück zum Zitat Sorger D, Patt M, Kumar P, Wiebe LI, Barthel H, Seese A, et al. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 2003;30(3):317–26.PubMedCrossRef Sorger D, Patt M, Kumar P, Wiebe LI, Barthel H, Seese A, et al. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 2003;30(3):317–26.PubMedCrossRef
12.
Zurück zum Zitat Reischl G, Dorow DS, Cullinane C, Katsifis A, Roselt P, Binns D, et al. Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA–first small animal PET results. J Pharm Pharm Sci 2007;10(2):203–11.PubMed Reischl G, Dorow DS, Cullinane C, Katsifis A, Roselt P, Binns D, et al. Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA–first small animal PET results. J Pharm Pharm Sci 2007;10(2):203–11.PubMed
13.
Zurück zum Zitat Garcia-Parra R, Wood D, Shah RB, Siddiqui J, Hussain H, Park H, et al. Investigation on tumor hypoxia in resectable primary prostate cancer as demonstrated by 18F-FAZA PET/CT utilizing multimodality fusion techniques. Eur J Nucl Med Mol Imaging 2011;38(10):1816–23.PubMedCrossRef Garcia-Parra R, Wood D, Shah RB, Siddiqui J, Hussain H, Park H, et al. Investigation on tumor hypoxia in resectable primary prostate cancer as demonstrated by 18F-FAZA PET/CT utilizing multimodality fusion techniques. Eur J Nucl Med Mol Imaging 2011;38(10):1816–23.PubMedCrossRef
14.
Zurück zum Zitat Souvatzoglou M, Grosu AL, Röper B, Krause BJ, Reischl G, Picchio M, et al. Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging 2007;34(10):1566–75.PubMedCrossRef Souvatzoglou M, Grosu AL, Röper B, Krause BJ, Reischl G, Picchio M, et al. Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging 2007;34(10):1566–75.PubMedCrossRef
15.
Zurück zum Zitat Schuetz M, Schmid MP, Pötter R, Kommata S, Georg D, Lukic D, et al. Evaluating repetitive 18F-fluoroazomycin-arabinoside (18FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical cancer. Acta Oncol 2010;49(7):941–7.PubMedCrossRef Schuetz M, Schmid MP, Pötter R, Kommata S, Georg D, Lukic D, et al. Evaluating repetitive 18F-fluoroazomycin-arabinoside (18FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical cancer. Acta Oncol 2010;49(7):941–7.PubMedCrossRef
16.
Zurück zum Zitat Busk M, Munk OL, Jakobsen S, Wang T, Skals M, Steiniche T, et al. Assessing hypoxia in animal tumor models based on pharmacokinetic analysis of dynamic FAZA PET. Acta Oncol 2010;49(7):922–33.PubMedCrossRef Busk M, Munk OL, Jakobsen S, Wang T, Skals M, Steiniche T, et al. Assessing hypoxia in animal tumor models based on pharmacokinetic analysis of dynamic FAZA PET. Acta Oncol 2010;49(7):922–33.PubMedCrossRef
17.
Zurück zum Zitat Shi K, Souvatzoglou M, Astner ST, Vaupel P, Nüsslin F, Wilkens JJ, et al. Quantitative assessment of hypoxia kinetic models by a cross-study of dynamic 18F-FAZA and 15O-H2O in patients with head and neck tumors. J Nucl Med 2010;51(9):1386–94.PubMedCrossRef Shi K, Souvatzoglou M, Astner ST, Vaupel P, Nüsslin F, Wilkens JJ, et al. Quantitative assessment of hypoxia kinetic models by a cross-study of dynamic 18F-FAZA and 15O-H2O in patients with head and neck tumors. J Nucl Med 2010;51(9):1386–94.PubMedCrossRef
18.
Zurück zum Zitat Reischl G, Ehrlichmann W, Bieg C, Solbach C, Kumar P, Wiebe LI, et al. Preparation of the hypoxia imaging PET tracer [18F]FAZA: reaction parameters and automation. Appl Radiat Isot 2005;62(6):897–901.PubMedCrossRef Reischl G, Ehrlichmann W, Bieg C, Solbach C, Kumar P, Wiebe LI, et al. Preparation of the hypoxia imaging PET tracer [18F]FAZA: reaction parameters and automation. Appl Radiat Isot 2005;62(6):897–901.PubMedCrossRef
19.
Zurück zum Zitat Windhorst AD, Linden TT, de Nooij A, Keus JF, Buijs FL, Schollema PE, et al. A complete, multipurpose, low cost, fully automated and GMP compliant radiosynthesis system. J Labelled Comp Radiopharm 2001;44(Suppl S1):S1052–4.CrossRef Windhorst AD, Linden TT, de Nooij A, Keus JF, Buijs FL, Schollema PE, et al. A complete, multipurpose, low cost, fully automated and GMP compliant radiosynthesis system. J Labelled Comp Radiopharm 2001;44(Suppl S1):S1052–4.CrossRef
20.
Zurück zum Zitat Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med 2009;50 Suppl 1:11S–20.PubMedCrossRef Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med 2009;50 Suppl 1:11S–20.PubMedCrossRef
21.
Zurück zum Zitat Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010;37(1):181–200.PubMedCrossRef Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010;37(1):181–200.PubMedCrossRef
22.
Zurück zum Zitat Boellaard R, van Lingen A, van Balen SC, Hoving BG, Lammertsma AA. Characteristics of a new fully programmable blood sampling device for monitoring blood radioactivity during PET. Eur J Nucl Med 2001;28(1):81–9.PubMedCrossRef Boellaard R, van Lingen A, van Balen SC, Hoving BG, Lammertsma AA. Characteristics of a new fully programmable blood sampling device for monitoring blood radioactivity during PET. Eur J Nucl Med 2001;28(1):81–9.PubMedCrossRef
23.
Zurück zum Zitat Gunn RN, Gunn SR, Cunningham VJ. Positron emission tomography compartmental models. J Cereb Blood Flow Metab 2001;21(6):635–52.PubMedCrossRef Gunn RN, Gunn SR, Cunningham VJ. Positron emission tomography compartmental models. J Cereb Blood Flow Metab 2001;21(6):635–52.PubMedCrossRef
24.
Zurück zum Zitat Yaqub M, Boellaard R, Kropholler MA, Lammertsma AA. Optimization algorithms and weighting factors for analysis of dynamic PET studies. Phys Med Biol 2006;51(17):4217–32.PubMedCrossRef Yaqub M, Boellaard R, Kropholler MA, Lammertsma AA. Optimization algorithms and weighting factors for analysis of dynamic PET studies. Phys Med Biol 2006;51(17):4217–32.PubMedCrossRef
25.
Zurück zum Zitat Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ, et al. Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab 1996;16(1):42–52.PubMedCrossRef Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ, et al. Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab 1996;16(1):42–52.PubMedCrossRef
26.
Zurück zum Zitat Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control 1974;AC-19:716–23.CrossRef Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control 1974;AC-19:716–23.CrossRef
27.
Zurück zum Zitat Glatting G, Kletting P, Reske SN, Hohl K, Ring C. Choosing the optimal fit function: comparison of the Akaike information criterion and the F-test. Med Phys 2007;34(11):4285–92.PubMedCrossRef Glatting G, Kletting P, Reske SN, Hohl K, Ring C. Choosing the optimal fit function: comparison of the Akaike information criterion and the F-test. Med Phys 2007;34(11):4285–92.PubMedCrossRef
28.
Zurück zum Zitat Sugawara Y, Zasadny KR, Neuhoff AW, Wahl RL. Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology 1999;213(2):521–5.PubMed Sugawara Y, Zasadny KR, Neuhoff AW, Wahl RL. Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology 1999;213(2):521–5.PubMed
29.
Zurück zum Zitat Chan T. Computerized method for automatic evaluation of lean body mass from PET/CT: comparison with predictive equations. J Nucl Med 2012;53(1):130–7.PubMedCrossRef Chan T. Computerized method for automatic evaluation of lean body mass from PET/CT: comparison with predictive equations. J Nucl Med 2012;53(1):130–7.PubMedCrossRef
30.
Zurück zum Zitat Busk M, Horsman MR, Jakobsen S, Bussink J, van der Kogel A, Overgaard J. Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imaging 2008;35(12):2294–303.PubMedCrossRef Busk M, Horsman MR, Jakobsen S, Bussink J, van der Kogel A, Overgaard J. Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imaging 2008;35(12):2294–303.PubMedCrossRef
31.
Zurück zum Zitat Maier FC, Kneilling M, Reischl G, Cay F, Bukala D, Schmid A, et al. Significant impact of different oxygen breathing conditions on noninvasive in vivo tumor-hypoxia imaging using [18F]-fluoro-azomycinarabino-furanoside ([18F]FAZA). Radiat Oncol 2011;6(1):165.PubMedCrossRef Maier FC, Kneilling M, Reischl G, Cay F, Bukala D, Schmid A, et al. Significant impact of different oxygen breathing conditions on noninvasive in vivo tumor-hypoxia imaging using [18F]-fluoro-azomycinarabino-furanoside ([18F]FAZA). Radiat Oncol 2011;6(1):165.PubMedCrossRef
32.
Zurück zum Zitat Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P, et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 2005;46(1):106–13.PubMed Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P, et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 2005;46(1):106–13.PubMed
33.
Zurück zum Zitat Cheebsumon P, Yaqub M, van Velden FH, Hoekstra OS, Lammertsma AA, Boellaard R. Impact of [(18)F]FDG PET imaging parameters on automatic tumour delineation: need for improved tumour delineation methodology. Eur J Nucl Med Mol Imaging 2011;38(12):2136–44.PubMedCrossRef Cheebsumon P, Yaqub M, van Velden FH, Hoekstra OS, Lammertsma AA, Boellaard R. Impact of [(18)F]FDG PET imaging parameters on automatic tumour delineation: need for improved tumour delineation methodology. Eur J Nucl Med Mol Imaging 2011;38(12):2136–44.PubMedCrossRef
34.
Zurück zum Zitat Koh WJ, Rasey JS, Evans ML, Grierson JR, Lewellen TK, Graham MM, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992;22(1):199–212.PubMedCrossRef Koh WJ, Rasey JS, Evans ML, Grierson JR, Lewellen TK, Graham MM, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992;22(1):199–212.PubMedCrossRef
35.
Zurück zum Zitat Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996;36(2):417–28.PubMedCrossRef Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996;36(2):417–28.PubMedCrossRef
Metadaten
Titel
Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patients
verfasst von
Eline E. Verwer
Floris H. P. van Velden
Idris Bahce
Maqsood Yaqub
Robert C. Schuit
Albert D. Windhorst
Pieter Raijmakers
Adriaan A. Lammertsma
Egbert F. Smit
Ronald Boellaard
Publikationsdatum
01.10.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 10/2013
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-013-2462-3

Weitere Artikel der Ausgabe 10/2013

European Journal of Nuclear Medicine and Molecular Imaging 10/2013 Zur Ausgabe